Karuna Therapeutics Inc KRTX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/07/21 EDT
114.89UNCH (UNCH)
Volume
23,263
Close
114.89quote price arrow up+3.29 (+2.95%)
Volume
84,117
52 week range
69.58 - 146.97

...

Loading . . .
  • Open112.85
  • Day High116.73
  • Day Low110.36
  • Prev Close114.89
  • 52 Week High146.97
  • 52 Week High Date02/09/21
  • 52 Week Low69.58
  • 52 Week Low Date09/04/20

Key Stats

  • Market Cap3.385B
  • Shares Out29.46M
  • 10 Day Average Volume0.11M
  • Dividend-
  • Dividend Yield-
  • Beta
  • YTD % Change13.09

KEY STATS

  • Open112.85
  • Day High116.73
  • Day Low110.36
  • Prev Close114.89
  • 52 Week High146.97
  • 52 Week High Date02/09/21
  • 52 Week Low69.58
  • 52 Week Low Date09/04/20
  • Market Cap3.385B
  • Shares Out29.46M
  • 10 Day Average Volume0.11M
  • Dividend-
  • Dividend Yield-
  • Beta
  • YTD % Change13.09

RATIOS/PROFITABILITY

  • EPS (TTM)-2.58
  • P/E (TTM)-44.48
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-71.671M
  • ROE (MRQ)-18.81%
  • Revenue (MRQ)0.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date08/03/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Karuna Therapeutics Inc

Latest From Our Partners

Profile

MORE
Karuna Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to address disabling neuropsychiatric conditions. Its lead product candidate, KarXT, is an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. It is initially developing KarXT, for the treatment of acute psychosis in patients with schizophrenia. The Company is developing a pipeline...
Steven Paul M.D.
Chairman
Andrew Miller Ph.D.
Chief Operating Officer
Troy Ignelzi
Chief Financial Officer
Giorgio Attardo Ph.D.
Vice President
Address
99 High Street, 26Th Floor
Boston, MA
02110
United States

Top Peers

SYMBOLLASTCHG%CHG
RETA
Reata Pharmaceuticals Inc
85.06-8.22-8.81%
ARVN
Arvinas Inc
63.63+0.48+0.76%
RCKT
Rocket Pharmaceuticals Inc
43.77+0.58+1.34%
TPTX
Turning Point Therapeutics Inc
64.96+0.18+0.28%
ITCI
Intra-Cellular Therapies Inc
35.03+1.60+4.79%